These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 9407423)
21. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. Ellis D; Moritz ML; Vats A; Janosky JE Am J Hypertens; 2004 Oct; 17(10):928-35. PubMed ID: 15485756 [TBL] [Abstract][Full Text] [Related]
22. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. Falk RJ; Scheinman J; Phillips G; Orringer E; Johnson A; Jennette JC N Engl J Med; 1992 Apr; 326(14):910-5. PubMed ID: 1542341 [TBL] [Abstract][Full Text] [Related]
23. Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy. Gosse P; Roudaut R; Herrero G; Dallocchio M J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S145-50. PubMed ID: 11527119 [TBL] [Abstract][Full Text] [Related]
24. Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure. Hard end-points and influence of proteinuria. Kamper AL; Strandgaard S; Leyssac PP Nephrol Dial Transplant; 1995; 10(7):1182-8. PubMed ID: 7478121 [TBL] [Abstract][Full Text] [Related]
25. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients. Draman CR; Kong NC; Gafor AH; Rahman AF; Zainuddin S; Mustaffa WM; Radzi AM; Shamsul AS Singapore Med J; 2008 Nov; 49(11):924-9. PubMed ID: 19037561 [TBL] [Abstract][Full Text] [Related]
26. Enzyme replacement therapy and Fabry nephropathy. Warnock DG; Daina E; Remuzzi G; West M Clin J Am Soc Nephrol; 2010 Feb; 5(2):371-8. PubMed ID: 20007680 [TBL] [Abstract][Full Text] [Related]
27. Short-term effect of angiotensin-converting enzyme inhibitor enalapril in incipient diabetic nephropathy. Abu-Romeh SH; Nawaz MK; Ali JH; Al-Suhaili AR; Abu-Jayyab AK Clin Nephrol; 1989 Jan; 31(1):18-21. PubMed ID: 2536602 [TBL] [Abstract][Full Text] [Related]
28. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Lebovitz HE; Wiegmann TB; Cnaan A; Shahinfar S; Sica DA; Broadstone V; Schwartz SL; Mengel MC; Segal R; Versaggi JA Kidney Int Suppl; 1994 Feb; 45():S150-5. PubMed ID: 8158885 [TBL] [Abstract][Full Text] [Related]
29. Blood pressure and progression of renal failure in the elderly. Acone D; Cante D; Cillo F; Giordano G; Giordano C Kidney Int Suppl; 1996 Jun; 55():S75-7. PubMed ID: 8743516 [TBL] [Abstract][Full Text] [Related]
30. ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients. van der Kleij FG; Navis GJ; Gansevoort RT; Heeg JE; Scheffer H; de Zeeuw D; de Jong PE Nephrol Dial Transplant; 1997; 12 Suppl 2():42-6. PubMed ID: 9269699 [TBL] [Abstract][Full Text] [Related]
31. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. van Essen GG; Rensma PL; de Zeeuw D; Sluiter WJ; Scheffer H; Apperloo AJ; de Jong PE Lancet; 1996 Jan; 347(8994):94-5. PubMed ID: 8538349 [TBL] [Abstract][Full Text] [Related]
32. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Ruggenenti P; Perna A; Gherardi G; Garini G; Zoccali C; Salvadori M; Scolari F; Schena FP; Remuzzi G Lancet; 1999 Jul; 354(9176):359-64. PubMed ID: 10437863 [TBL] [Abstract][Full Text] [Related]
33. Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. Apperloo AJ; de Zeeuw D; Sluiter HE; de Jong PE BMJ; 1991 Oct; 303(6806):821-4. PubMed ID: 1932973 [TBL] [Abstract][Full Text] [Related]
34. Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. Omata K; Kanazawa M; Sato T; Abe F; Saito T; Abe K Kidney Int Suppl; 1996 Jun; 55():S57-62. PubMed ID: 8743512 [TBL] [Abstract][Full Text] [Related]
35. Randomized controlled trial: lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy. Amara AB; Sharma A; Alexander JL; Alfirevic A; Mohiuddin A; Pirmohamed M; Close GL; Grime S; Maltby P; Shawki H; Heyworth S; Shenkin A; Smith L; Sharma AK; Hammad A; Rustom R Transplantation; 2010 Jan; 89(1):104-14. PubMed ID: 20061926 [TBL] [Abstract][Full Text] [Related]
36. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Gansevoort RT; Sluiter WJ; Hemmelder MH; de Zeeuw D; de Jong PE Nephrol Dial Transplant; 1995 Nov; 10(11):1963-74. PubMed ID: 8643149 [TBL] [Abstract][Full Text] [Related]
37. [Therapy with ACE inhibitors in chronic heart failure and limited kidney function]. Osterziel KJ; Nagel F; Dietz R Z Kardiol; 1994; 83 Suppl 4():81-7. PubMed ID: 7856286 [TBL] [Abstract][Full Text] [Related]
38. Total and split renal function in patients with renovascular hypertension: effects of angiotensin-converting enzyme inhibition. Reams GP; Singh A; Logan KW; Holmes RA; Bauer JH J Clin Hypertens; 1987 Jun; 3(2):153-63. PubMed ID: 3039075 [TBL] [Abstract][Full Text] [Related]
39. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hausberg M; Barenbrock M; Hohage H; Müller S; Heidenreich S; Rahn KH Hypertension; 1999 Mar; 33(3):862-8. PubMed ID: 10082500 [TBL] [Abstract][Full Text] [Related]
40. Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE inhibition. Chuahirun T; Wesson DE Am J Kidney Dis; 2002 Feb; 39(2):376-82. PubMed ID: 11840380 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]